Summit Therapeutics Plc Stock Analysis

SMMT Stock  USD 20.69  2.20  11.90%   
Summit Therapeutics PLC is undervalued with Real Value of 26.38 and Target Price of 32.15. The main objective of Summit Therapeutics stock analysis is to determine its intrinsic value, which is an estimate of what Summit Therapeutics PLC is worth, separate from its market price. There are two main types of Summit Therapeutics' stock analysis: fundamental analysis and technical analysis.
The Summit Therapeutics stock is traded in the USA on NASDAQ Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. Summit Therapeutics is usually not traded on Labour Day, Thanksgiving Day, Christmas Day, New Year 's Day, National Mourning Day, Dr . Martin Luther King Jr 's Birthday, Washington 's Birthday, Good Friday, Memorial Day, Juneteenth Holiday, Independence Day. Summit Stock trading window is adjusted to America/New York timezone.
  
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Summit Therapeutics PLC. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population.

Summit Stock Analysis Notes

About 84.0% of the company outstanding shares are owned by corporate insiders. The company recorded a loss per share of 0.31. Summit Therapeutics PLC had not issued any dividends in recent years. The entity had 1:1 split on the 21st of September 2020. Summit Therapeutics Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat infectious diseases in the United States and Latin America. The company was founded in 2003 and is based in Cambridge, Massachusetts. Summit Therapeu operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 105 people. To find out more about Summit Therapeutics PLC contact Robert Duggan at 650 460 8308 or learn more at https://www.summittxinc.com.

Summit Therapeutics PLC Investment Alerts

Summit Therapeutics had very high historical volatility over the last 90 days
Net Loss for the year was (221.31 M) with profit before overhead, payroll, taxes, and interest of 705 K.
Summit Therapeutics PLC currently holds about 121.97 M in cash with (142.11 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.61.
Summit Therapeutics has a poor financial position based on the latest SEC disclosures
Roughly 84.0% of the company outstanding shares are owned by corporate insiders
Latest headline from benzinga.com: This CoStar Group Analyst Begins Coverage On A Bullish Note Here Are Top 5 Initiations For Friday

Summit Therapeutics PLC Upcoming and Recent Events

14th of March 2024
Upcoming Quarterly Report
View
31st of December 2023
Next Fiscal Quarter End
View

Summit Largest EPS Surprises

Earnings surprises can significantly impact Summit Therapeutics' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Reported
Fiscal Date
Estimated EPS
Reported EPS
Surprise
2024-10-30
2024-09-30-0.07-0.08-0.0114 
2024-08-06
2024-06-30-0.06-0.09-0.0350 
2019-06-26
2019-03-31-0.16-0.2-0.0425 
View All Earnings Estimates

Summit Therapeutics Environmental, Social, and Governance (ESG) Scores

Summit Therapeutics' ESG score is a quantitative measure that evaluates Summit Therapeutics' performance and commitment regarding environmental, social, and governance (ESG) factors. These scores are becoming increasingly crucial in investment decision-making processes, providing insights into non-financial aspects of Summit Therapeutics' operations that may have significant financial implications and affect Summit Therapeutics' stock price as well as guide investors towards more socially responsible investments.

Summit Therapeutics Thematic Classifications

In addition to having Summit Therapeutics stock in your portfolios, you can add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your favorite investment opportunity, you can then obtain an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility. If you are a result-oriented investor, you can benefit from optimizing one of our existing themes to build an efficient portfolio against your specific investing outlook.
Biotech Idea
Biotech
Biotechnology and pharmaceuticals production and services
Health Management Idea
Health Management
Healthcare providers, hospitals
Israel Wall Street Idea
Israel Wall Street
Large Israel companies traded on major USA exchanges

Summit Stock Institutional Investors

Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
Shares
Rock Springs Capital Management Lp2024-12-31
1.1 M
Goldman Sachs Group Inc2024-12-31
910 K
Northern Trust Corp2024-12-31
871.4 K
Candriam Luxembourg S.c.a.2024-12-31
842.6 K
Td Asset Management Inc2024-12-31
838 K
Pictet Asset Manangement Sa2024-09-30
691.4 K
Citadel Advisors Llc2024-09-30
650.8 K
Morgan Stanley - Brokerage Accounts2024-12-31
561 K
Twin Tree Management, Lp2024-12-31
495.8 K
Baker Bros Advisors Lp2024-12-31
24.4 M
Vanguard Group Inc2024-12-31
11.7 M
Note, although Summit Therapeutics' institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Summit Market Capitalization

The company currently falls under 'Large-Cap' category with a current market capitalization of 15.26 B.

Summit Profitablity

Last ReportedProjected for Next Year
Return On Tangible Assets(0.51)(0.54)
Return On Assets(0.51)(0.53)
Return On Equity(0.57)(0.60)

Management Efficiency

Summit Therapeutics PLC has return on total asset (ROA) of (0.4131) % which means that it has lost $0.4131 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.949) %, meaning that it created substantial loss on money invested by shareholders. Summit Therapeutics' management efficiency ratios could be used to measure how well Summit Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. Return On Capital Employed is likely to gain to 0.0008 in 2025, whereas Return On Tangible Assets are likely to drop (0.54) in 2025. At this time, Summit Therapeutics' Total Current Liabilities is comparatively stable compared to the past year. Liabilities And Stockholders Equity is likely to gain to about 457.3 M in 2025, whereas Non Current Liabilities Total is likely to drop slightly above 4.8 M in 2025.
Last ReportedProjected for Next Year
Book Value Per Share 0.54  0.61 
Net Current Asset Value128.1 K113.8 K
Tangible Asset Value47 M49.4 M
Tangible Book Value Per Share 0.54  0.43 
Enterprise Value Over EBITDA40.7 K42.7 K
Price Book Value Ratio 32.99  31.34 
Enterprise Value Multiple40.7 K42.7 K
Price Fair Value 32.99  31.34 
Enterprise Value12.7 B13.4 B
Summit Therapeutics PLC has shown resilience through effective management strategies. Our analysis examines how these strategies influence financial outcomes and investor returns which helps in understanding the stock's long-term potential.
Beta
(0.88)
Return On Assets
(0.41)
Return On Equity
(0.95)

Technical Drivers

As of the 1st of March, Summit Therapeutics has the Coefficient Of Variation of 1685.34, risk adjusted performance of 0.0523, and Semi Deviation of 4.59. In relation to fundamental indicators, the technical analysis model makes it possible for you to check existing technical drivers of Summit Therapeutics PLC, as well as the relationship between them.

Summit Therapeutics PLC Price Movement Analysis

Execute Study
Incorrect Input. Please change your parameters or increase the time horizon required for running this function. The output start index for this execution was zero with a total number of output elements of zero. The Bollinger Bands is very popular indicator that was developed by John Bollinger. It consist of three lines. Summit Therapeutics middle band is a simple moving average of its typical price. The upper and lower bands are (N) standard deviations above and below the middle band. The bands widen and narrow when the volatility of the price is higher or lower, respectively. The upper and lower bands can also be interpreted as price targets for Summit Therapeutics PLC. When the price bounces off of the lower band and crosses the middle band, then the upper band becomes the price target.

Summit Therapeutics PLC Insider Trading Activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Summit Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Summit Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Summit Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
 
Xia Yu over a month ago
Acquisition by Xia Yu of 200000 shares of Summit Therapeutics at 2.64 subject to Rule 16b-3
 
Bhaskar Anand over a month ago
Acquisition by Bhaskar Anand of 75000 shares of Summit Therapeutics at 17.85 subject to Rule 16b-3
 
Booth Robert F. over a month ago
Acquisition by Booth Robert F. of 6855 shares of Summit Therapeutics at 18.35 subject to Rule 16b-3
 
Clark Kenneth A over three months ago
Acquisition by Clark Kenneth A of 200000 shares of Summit Therapeutics at 19.95 subject to Rule 16b-3
 
Mahatme Ujwala over three months ago
Acquisition by Mahatme Ujwala of 40500 shares of Summit Therapeutics at 1.67 subject to Rule 16b-3
 
Zanganeh Mahkam over six months ago
Acquisition by Zanganeh Mahkam of 100000 shares of Summit Therapeutics at 1.29 subject to Rule 16b-3
 
Wang Luhua over six months ago
Insider Trading
 
Booth Robert F. over six months ago
Acquisition by Booth Robert F. of 32700 shares of Summit Therapeutics at 1.67 subject to Rule 16b-3
 
Zanganeh Mahkam over six months ago
Acquisition by Zanganeh Mahkam of 20000 shares of Summit Therapeutics at 3.71 subject to Rule 16b-3
 
Booth Robert F. over six months ago
Acquisition by Booth Robert F. of 6250 shares of Summit Therapeutics subject to Rule 16b-3
 
Robert Duggan over a year ago
Acquisition by Robert Duggan of 74545 shares of Summit Therapeutics subject to Rule 16b-3
 
Zanganeh Mahkam over a year ago
Exercise of in-the-money or at-the-money derivative position by Zanganeh Mahkam of 489814 shares of Summit Therapeutics

Summit Therapeutics Outstanding Bonds

Summit Therapeutics issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Summit Therapeutics PLC uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Summit bonds can be classified according to their maturity, which is the date when Summit Therapeutics PLC has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.

Summit Therapeutics Predictive Daily Indicators

Summit Therapeutics intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Summit Therapeutics stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.

Summit Therapeutics Corporate Filings

8K
24th of February 2025
Report filed with the SEC to announce major events that shareholders should know about
ViewVerify
8K
24th of January 2025
Report filed with the SEC to announce major events that shareholders should know about
ViewVerify
F4
14th of January 2025
The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities
ViewVerify
8K
13th of January 2025
Report filed with the SEC to announce major events that shareholders should know about
ViewVerify
F4
6th of January 2025
The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities
ViewVerify
8K
30th of October 2024
Report filed with the SEC to announce major events that shareholders should know about
ViewVerify
F4
15th of October 2024
The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities
ViewVerify
F4
3rd of October 2024
The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities
ViewVerify

Summit Therapeutics Forecast Models

Summit Therapeutics' time-series forecasting models are one of many Summit Therapeutics' stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Summit Therapeutics' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

About Summit Stock Analysis

Stock analysis is the technique used by a trader or investor to examine and evaluate how Summit Therapeutics prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Summit shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Summit Therapeutics. By using and applying Summit Stock analysis, traders can create a robust methodology for identifying Summit entry and exit points for their positions.
Last ReportedProjected for Next Year
Pretax Profit Margin(128.64)(122.21)
Operating Profit Margin(117.71)(111.82)
Net Loss(121.45)(115.38)
Gross Profit Margin(2.95)(2.81)

Current Summit Analysis - Recommendations

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Summit analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Summit analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Target PriceAdvice# of Analysts
32.15Strong Buy7Odds
Summit Therapeutics PLC current and past analyst recommendations published by a number of research institutions as well as average analyst consensus.
Most Summit analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Summit stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Summit Therapeutics PLC, talking to its executives and customers, or listening to Summit conference calls.
Summit Analyst Advice Details

Summit Stock Analysis Indicators

Summit Therapeutics PLC stock analysis indicators help investors evaluate how Summit Therapeutics stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Summit Therapeutics shares will generate the highest return on investment. By understating and applying Summit Therapeutics stock analysis, traders can identify Summit Therapeutics position entry and exit signals to maximize returns.
Begin Period Cash Flow71.4 M
Common Stock Shares Outstanding718.5 M
Total Stockholder Equity388.7 M
Property Plant And Equipment Net7.4 M
Cash And Short Term Investments412.3 M
Cash104.9 M
Accounts Payable4.6 M
Net Debt-97.6 M
50 Day M A19.8202
Total Current Liabilities41.7 M
Other Operating Expenses226.3 M
Non Current Assets Total11.8 M
Non Currrent Assets Other2.5 M
Stock Based Compensation51 M

Additional Tools for Summit Stock Analysis

When running Summit Therapeutics' price analysis, check to measure Summit Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Summit Therapeutics is operating at the current time. Most of Summit Therapeutics' value examination focuses on studying past and present price action to predict the probability of Summit Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Summit Therapeutics' price. Additionally, you may evaluate how the addition of Summit Therapeutics to your portfolios can decrease your overall portfolio volatility.